The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

This study is testing a combination of two diabetes/weight-loss medications — an SGLT2 inhibitor and a GLP-1 receptor agonist — to see if they can improve kidney function, blood sugar control, and weight in kidney transplant recipients. **You may be eligible if...** - You are 18 or older and have received a kidney transplant - It has been more than 3 months since your transplant - Your kidney is functioning at a moderate level (eGFR at least 20 ml/min) - Your blood pressure is within a manageable range - Your BMI is between 18.5 and 40 kg/m² - You have type 2 diabetes or are overweight with additional risk factors **You may NOT be eligible if...** - You have type 1 diabetes - You have very poor kidney function - You have had recent serious infections or other transplant complications - You are pregnant or planning to become pregnant - You have had recurrent urinary tract infections Talk to your doctor to see if this trial is right for you.